Involvement of fatty acid metabolism in the hepatotoxicity induced by divalproex sodium

Human and Experimental Toxicology

Volumn 31, Issue 11, 2012, Pages 1092-1101

  Wang, W ^a   Lin, R ^a   Zhang, J ^a   Mao, Y ^b   Bu, X ^b   Ji, Q ^a   Zhai, X ^b   Lin, Q ^a   Yang, L ^a   Zhang, K ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi's Tiansen Drug Research and Development Limited Company   (China)

Author keywords

Divalproex sodium; fatty acid metabolism; hepatotoxicity; PPAR ; SREBP 1c

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE; LACTATE DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; VALPROATE SEMISODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID METABOLISM; LIVER CELL; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ACETYLTRANSFERASES; ALANINE TRANSAMINASE; ANIMALS; ANTICONVULSANTS; ASPARTATE AMINOTRANSFERASES; CELL SURVIVAL; DRUG-INDUCED LIVER INJURY; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; HEPATOCYTES; L-LACTATE DEHYDROGENASE; MALE; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STEAROYL-COA DESATURASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; VALPROIC ACID;

EID: 84869005234     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327112444477     Document Type: Article

References (46)

1. Physicians' desk reference. New Jersey: Medical Economics Company ; 2002 :
2. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995 ; 36: S2 - S12
3. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002 ; 58: 1652-1659
4. Silberstein SD, Wilmore LJ. Divalproex sodium: migraine treatment and monitoring. Headache. 1996 ; 36: 239-242
5. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Carbiovasc Dis. 2009 ; 19: 291-303
6. Ji QL, Shi XL, Lin R, et al. Participation of lipid transport and fatty acid metabolism in valproate sodium-induced hepatotoxicity in HepG2 cells. Toxicol Vitro. 2010 ; 24: 1086-1091
7. Kersten S. Effects of fatty acids on gene expression: role of peroxisome proliferator-activated receptor alpha liver X receptor alpha and sterol regulatory element-binding protein-1c. Proc Nutr Soc. 2002 ; 61: 371-374
8. Bennett MK, Lopez JM, Sanchez HB, Osborne TF. Sterol regulation of fatty-acid synthase promoter-coordinate feedback-regulation of two major lipid pathways. J Biol Chem. 1995 ; 270: 25578-25583
9. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 1996 ; 10: 1096-1107
10. van Raalte H, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res. 2004 ; 21: 1531-1538
11. Yoshikawa T, Ide T, Shimano H, et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol Endocrinol. 2003 ; 17: 1240-1254
12. Kast-Woelbern HR, Dana SL, Cesario RM, et al. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis. J Biol Chem. 2004 ; 279: 23908-23915
13. Ferno J, Vik-Mo A, Jassim G, et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology. 2009 ; 203: 73-84
14. Lauressergues E, Staels B, Valeille K, et al. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn-Schmiedebergs Arch Pharmacol. 2010 ; 381: 427-439
15. Voss KA, Liu J, Anderson SP, et al. Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor alpha. Toxicol Sci. 2006 ; 68: 108-119
16. Luci S, Giemsa B, Kluge H, Eder K. Clofibrate causes an upregulation of PPAR-alpha target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs. Am J Physiol Regul Integr Comp Physiol. 2007 ; 293: R70 - R77
17. MeadeEM. Sodium hydrogen divalproate oligomer. US Patent 4988731, 1991.
18. MeadeEM. Sodium hydrogen divalproate oligomer. US Patent 5212326, 1993.
19. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol. 1976 ; 13: 29-83
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 ; 65: 55-63
21. Legrand C, Bour JM, Jacob C, et al. Lactate dehydrogenase (LDH) activity of the number of dead cells in the medium of cultured eukaryotic cells as marker. J Biotechnol. 1992 ; 25: 231-243
22. Ostapowicz G, Lee YH. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol. 2000 ; 15: 480-488
23. Bulle F, Mavier P, Zafrani ES, et al. Mechanism of gamma-glutamyl transpeptidase release in serum during intrahepatic and extrahepatic cholestasis in the rat-a histochemical, biochemical and molecular approach. Hepatology. 1990 ; 11: 545-550
24. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatr. 2001 ; 9: 58-66
25. Bernstein JE, Henninger DA, Phillips SB. Prevention of drug-induced liver toxicity. Gastroenterology. 2008 ; 134: A822 - A822
26. Redden L, DelBello M, Wagner KD, et al. Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol. 2009 ; 19: 83-89
27. Matsuzaka T, Shimano H, Yahagi N, et al. Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPAR alpha. J Lipid Res. 2002 ; 43: 107-114
28. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 2001 ; 40: 439-452
29. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002 ; 109: 1125-1131
30. Ferno J, Raeder MB, Vik-Mo AO, et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?. Pharmacogenomics J. 2005 ; 5: 298-304
31. Harwood HJ, Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem. 2003 ; 278: 37099-37111
32. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry. 1989 ; 28: 4523-4530
33. Witkowski A, Rangan VS, Randhawa ZI, et al. Structural organization of the multifunctional animal fatty-acid synthase. FEBS J. 1991 ; 198: 571-579
34. Ntambi JM, Miyazaki A, Dobrzyn A. Regulation of stearoyl-COA desaturase expression. Lipids. 2004 ; 39: 1061-1065
35. Raeder MB, Ferno J, Vik-Mo AO, Steen VM. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?. Mol Cell Biochem. 2006 ; 289: 167-173
36. Yin HQ, Kim YC, Chung YS, et al. Honokiol reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes. Toxicol Appl Pharmacol. 2009 ; 236: 124-130
37. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 2004 ; 61: 393-416
38. Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. Life Sci. 2006 ; 79: 1865-1872
39. LeMay C, Pineau T, Bigot K, et al. Reduced hepatic fatty acid oxidation in fasting PPAR alpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS Lett. 2000 ; 475: 163-166
40. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system-from concept to molecular analysis. FEBS J. 1997 ; 244: 1-14
41. JugeAubry C, Pernin A, Favez T, et al. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements-Importance of the 5'-flanking region. J Biol Chem. 1997 ; 272: 25252-25259
42. Britton CH, Schultz RA, Zhang B, et al. Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene. Proc Natl Acad Sci U S A. 1995 ; 92: 1984-1988
43. Fraser F, Corstorphine CG, Zammit VA. Topology of carnitine palmitoyltransferase I in the mitochondrial outer membrane. Biochem J. 1997 ; 323: 711-718
44. Mascaro C, Acosta E, Ortiz JA, et al. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem. 1998 ; 273: 8560-8563
45. Xiong Y, Yang YQ, Yang J, et al. Tectoridin, an isoflavone glycoside from the flower of Pueraria lobata, prevents acute ethanol-induced liver steatosis in mice. Toxicology. 2010 ; 276: 64-72
46. Kim JH, Kim D, Kim J, Hwang JK. Euchresta horsfieldii Benn. activates peroxisome proliferator-activated receptor alpha and regulates expression of genes involved in fatty acid metabolism in human HepG2 cells. J Ethnopharmacol. 2011 ; 133: 244-247